STK11 and lung cancer: Furthermore, LKB1 silencing diminishes the sensitivity of KRASG12C/LKB1Null-driven lung cancer to KRASG12C inhibition perhaps through the emergence of mixed adenosquamous cell carcinomas and mucinous adenocarcinomas.